调控Wnt/β-catenin通路促进抗肿瘤免疫浸润以增敏卵巢癌ICB治疗
该临床前研究在ID8p53-/-和MISIIR-Tag小鼠卵巢癌模型中评估Wnt抑制剂CGX-1321单用或联合DKN-01或抗PD-1的疗效。CGX-1321显著降低肿瘤负荷并增加TME中CD8+ T细胞浸润,但联合治疗未优于单药。
要点
- CGX-1321单药可降低卵巢癌小鼠模型肿瘤负荷并增加CD8+ T细胞浸润。
- CGX-1321联合DKN-01或抗PD-1未比单药进一步增加CD8+ T细胞。
- CGX-1321联合DKN-01是否增敏ICB治疗尚需进一步研究。
核心结论
- CGX-1321可显著降低卵巢癌小鼠模型肿瘤负荷并增加CD8+ T细胞水平。
- 联合DKN-01或抗PD-1未增强CGX-1321的上述效果。
研究设计与样本
- 临床前研究,使用ID8p53-/-和MISIIR-Tag小鼠卵巢癌模型。
- 评估CGX-1321单用或联合DKN-01或抗PD-1对肿瘤负荷和TME免疫细胞的影响。
- 采用流式细胞术和NanoString分析肿瘤内在信号和免疫相关谱。
主要发现
- CGX-1321在ID8p53-/-和MISIIR-Tag模型中显著减少肿瘤负荷并限制肿瘤进展。
- CGX-1321增加TME中浸润性CD8+ T细胞。
- CGX-1321联合DKN-01或抗PD-1也降低肿瘤负荷并增加网膜TME中CD8+ T细胞浸润,但未超过CGX-1321单药。
关键数值与推荐
- CGX-1321单药显著降低肿瘤负荷并增加CD8+ T细胞。
- 联合DKN-01或抗PD-1未在更大程度上增加CD8+ T细胞浸润。
临床怎么用
- Wnt抑制剂CGX-1321在临床前卵巢癌中显示免疫增强和抗肿瘤作用。
- 联合DKN-01或抗PD-1的增益未明确,需进一步研究验证增敏ICB的潜力。
局限性
- 研究为临床前小鼠模型,结果尚需临床验证。
- CGX-1321联合DKN-01是否增敏ICB治疗需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint blockade (ICB) therapy shows limited efficacy in ovarian cancers due to the "cold" immune phenotype surrounding these tumors. Previous studies have shown that in ovarian cancer Wnt/β-catenin pathway activation contributes to this immune phenotype. Here, we evaluated the anti-tumor and immune-enhancing properties of the Wnt inhibitor, CGX-1321, used alone or in combination with either DKN-01 or anti-PD-1 therapy, in pre-clinical ovarian cancer models. METHODS: The parental ID8 murine ovarian cancer model harboring a knock-out of p53 (ID8p53-/-) and MISIIR-Tag spontaneous ovarian cancer models were used to test the effects of CGX-1321 alone or in combination therapies on tumor burden and immune cell landscape in the tumor microenvironment (TME). Flow cytometry and NanoString analyses were used to characterize the changes in tumor-intrinsic signaling and immune-related profiles in the TME of ovarian cancer in response to treatments. RESULTS: CGX-1321 significantly reduced tumor burden and constrained tumor progression in the ID8p53-/- and MISIIR-Tag models. Furthermore, CGX-1321 increased infiltrating CD8+ T cells in the TME. Combining CGX-1321 with either DKN-01 or anti-PD-1 therapy also decreased tumor burden and increased CD8+ T cell infiltration in the omentum TME but did not do so to a greater extent that CGX-1321 monotherapy. CONCLUSIONS: CGX-1321 significantly reduced tumor burden and enhanced CD8+ T cell levels in ovarian cancer, nevertheless the addition of DKN-01 or anti-PD-1 therapies did not enhance these effects of CGX-1321. Further investigation is needed to determine if CGX-1321 + DKN-01 combination treatment sensitizes pre-clinical ovarian cancer to ICB therapy.
引用
- Wall JA, Meza-Perez S, Scalise CB, et al. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2020. PMID: 33168307. doi:10.1016/j.ygyno.2020.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。